AOL Money & Finance

Newspaper wrap-up 4-4-07: AstraZeneca may lose 38% of its revenue in next 5 years

More

MAJOR PAPERS:
OTHER PAPERS:
  • According to the U.K. Times, citing research by Prudential Equity Group and AXA Framlington, AstraZeneca (NYSE: AZN) could lose 38% of its revenue because key drug patents, including Arimi-dex, Seroquel and Symbicort, will expire in the next five years.
  • Investor's Business Daily's "The New America" column mentioned Israeli defense firm Elbit Systems Ltd. (NASDAQ: ESLT) positively. Elbit is a small, flexible company that works with industry giants such as the Boeing Co. (NYSE: BA).
Symbol Lookup
IndexesChangePrice
DJIA-17.2410,433.71
NASDAQ-6.832,169.18
S&P 500-0.591,105.65

Last updated: November 24, 2009: 09:09 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines